Preclinical studies of in vitro and in vivo models have shown that genetic ablation or antibody-mediated blockade of CD38 may boost the anti-tumor activity of cytotoxic T-cells directly—a finding that may be clinically relevant and speak in favor of continued, uninterrupted treatment with daratumumab [18]. Here, CD38 is linked to neoplasm.